BioSpace News Archive

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced that the protocol for its Phase 2 clinical study in PD and AD patients was submitted to the U.S. Food and Drug Administration.

Live Chat to Discuss Current Clinical and Translational Response to the Novel Coronavirus

Concert Pharmaceuticals, Inc. reported financial results for the first quarter of 2020..

Abiomed, Inc., a leading provider of breakthrough heart support technologies reported fourth quarter fiscal 2020 revenue of $206.7 million compared to revenue of $207.1 million for the same period of fiscal 2019.

Encompass Health Corp. announced it will participate in the UBS Virtual Global Healthcare Conference being held May 18‑20, 2020.

Torben Jørgensen, Chairman of the Board in Biotage AB, informed the company that he has sold part of his shareholding in Biotage on 29 April 2020.

InMed Pharmaceuticals Inc. announced it has received regulatory and ethics board approval of its Clinical Trial Application to conduct its second Phase 1 trial with INM-755.

Intellia Therapeutics, Inc. has named David Lebwohl, M.D., as its new executive vice president and chief medical officer.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $18.00 per share.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 8:30 a.m. EDT to report its financial results for the quarter ended March